# Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/nitazene-synthetic-opioids-temporary-schedule-i-placement/ > **Published:** 2026-03-08T19:45:11-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:26:18-04:00 > **Clinical Summary:** Learn about nitazene synthetic opioids and their temporary placement in Schedule I due to emerging abuse and overdose risks. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Regulations.gov PolicySafetyResearch Clinical Summary This federal action places two synthetic opioids, N-pyrrolidino metonitazene and N-pyrrolidino protonitazene, into Schedule I, reflecting their emergence as drugs of abuse with no accepted medical use. These nitazene compounds have appeared in illicit drug supplies and are associated with overdose deaths, particularly in combination with other opioids and depressants, creating a significant [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) threat. The temporary scheduling provides law enforcement and regulatory agencies tools to address the proliferation of these substances while the DEA continues to evaluate their abuse potential and whether permanent scheduling is warranted. Clinicians should be aware that patients presenting with unexplained opioid-like overdoses or unusual toxidromes may have been exposed to these novel synthetic opioids, which standard toxicology screens may not detect. This scheduling decision underscores the evolving landscape of illicit opioid analogs and the need for heightened clinical vigilance in overdose management. Clinicians should maintain awareness of emerging synthetic opioids in their communities and consider consulting poison control or specialty toxicology resources when managing suspected nitazene exposures. Clinical Perspective The DEA’s emergency scheduling of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene represents a regulatory response to emerging synthetic opioids that have appeared in illicit drug supplies, though [clinical data](https://cedclinic.com/uk-germany-medical-cannabis-markets-double-2025/) on their pharmacology and toxicology remain limited. These nitazene analogs have been detected in overdose deaths and drug seizures, suggesting potential for abuse and harm, yet healthcare providers have minimal guidance on recognizing their effects or managing intoxication since clinical experience is sparse and toxicology screening may not routinely detect them. The regulatory action addresses a real [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) threat in the context of the ongoing opioid crisis, but the speed of emergence of new analogs continues to outpace both clinical knowledge and detection capabilities. Clinicians encountering unexplained opioid-like overdoses with atypical presentations, particularly in patients using street drugs, should maintain awareness that novel 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Temporary+Placement+of+N-pyrrolidino+metonitazene+and+N-pyrrolid...+%40drcaplan&url=https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2024-0118-0001) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2024-0118-0001) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Temporary+Placement+of+N-pyrrolidino+metonitazene+and+N-pyrrolid...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2024-0118-0001) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.regulations.gov/document/DEA-2024-0118-0001](https://www.regulations.gov/document/DEA-2024-0118-0001) Further Reading Evidence Watch[`Cannabinoid Clinical Trials: CBD Cortical Excitability Study`](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Research Digest[Daily Digest 2026-03-07](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I](https://cedclinic.com/schedules-controlled-substances-placement-schedule-i/) Explore the regulatory placement of related nitazene compounds in Schedule I and their implications for public health and safety. [Read More](https://cedclinic.com/schedules-controlled-substances-placement-schedule-i/) [Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I](https://cedclinic.com/scheduling-novel-synthetic-opioids-schedule-i/) Review the scheduling of additional synthetic opioids related to nitazenes and their regulatory status. [Learn More](https://cedclinic.com/scheduling-novel-synthetic-opioids-schedule-i/) [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) Understand the temporary scheduling process for emerging synthetic substances including 2-Fluorodeschloroketamine. [Discover More](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).